Milestone Pharmaceuticals Inc. (MIST) research
Milestone Pharmaceuticals Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $0.81
- As of
Milestone Pharmaceuticals Inc. (MIST): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-03.
As of . Source: SEC EDGAR filings for MIST. Method and limitations.
Share the MIST intelligence card
See the full MIST dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for MIST on one page. Preview it with sample data, then open it live with a free account.
Preview the MIST dossierActive signals for MIST
- highCONSENSUS_BUY
3 tracked funds increased MIST this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
Point72 Asset Management, L.P. added +398% to MIST (2026Q2)
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +103% to MIST (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 76% of MIST (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 86% of MIST (2026Q2)
FREE, NO ACCOUNT
Every signal on MIST, as it fires
You are seeing 5 of 10 signals recorded on MIST since 2026-05-26.
The five above landed across 2 days. The other 5 were recorded on 2 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in MIST (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| Point72 Asset Management, L.P.CUSIP 59935V107 · 2026Q2 | $7.3M | 0.01% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 59935V107 · 2026Q2 | $4.2M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 59935V107 · 2026Q2 | $2.7M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 59935V107 · 2026Q2 | $44K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, MIST
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
MIST against its peers
MIST's return on equity of -151.0% ranks in the 38th percentile of 19 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-01-31.
| Metric | MIST | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 2.0M | n/a | 13 |
| Operating margin | n/a | -477.5% | n/a | 11 |
| Net margin | n/a | -738.3% | n/a | 12 |
| Return on equity | -151.0% | -101.0% | 38 | 19 |
Peers (22): NTRB, PLYX, MNOV, OKUR, ANIX, KZIA, PMN, NMRA, VXRT, PYPD, BDTX, IMUX, CRDF, BMEA, AARD, NRXS, RLYB, CBUS, LENZ, VANI, ICCC, RANI. Left out: HSTC (period gap), CNXU (no annual filing), SPRC (period gap). Fiscal periods ending between 2025-06-30 and 2026-01-31. Every figure is one full fiscal year read from one annual filing (MIST: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more MIST signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to MISTand get the insider, 13F, options, and confluence read in one view.